Patel: The kinetics bear this out: imaging slow decline along with protein marker decline; but ctDNA quickly diminishes. #MDxEU17
9:18am April 11th 2017 via Hootsuite
Patel: Protein markers are secreted from live cancer cells, while ctDNA is released from dying cancer cells w/active clearing #MDxEU17
9:17am April 11th 2017 via Hootsuite
Hmm. https://t.co/E3JHIEbcp9
9:13am April 11th 2017 via Hootsuite
Q: Expense for daily Dx use? O'Brien: 100€ per sample. #MDxEU17
7:28am April 11th 2017 via Hootsuite
O'Brien: qPCR gene expression from the CTCs isolated, looking at early stg Ov Ca, n=200 from Parsortix harvest #MDxEU17
7:26am April 11th 2017 via Hootsuite
O'Brien: Points to this Dec '15 ref https://t.co/S07vQ8Eue6 from CRUK (Dive group) Fig from '15 PLoS https://t.co/htPpGSCzbI #MDxEU17
7:24am April 11th 2017 via Hootsuite
O'Brien: 10mL of whole blood, can label cells in-cassette. 2K-5K WBC background (to pool collected CTCs) or feed DEPArray #MDxEU17
7:20am April 11th 2017 via Hootsuite
O'Brien: A stepped channel, the larger CTCs will get caught. Can be stained or reverse flushed. Shows video of device in action #MDxEU17
7:17am April 11th 2017 via Hootsuite
O'Brien: Parsortix - selection via size and deformability. Wanted a system to get cells recovered, from pt samples. #MDxEU17
7:14am April 11th 2017 via Hootsuite
O'Brien: CTC and ctDNA failed in 20-30%; when both 100% detected T790M in these samples #MDxEU17
7:12am April 11th 2017 via Hootsuite
O'Brien: Believe that CTC and ctDNAs are complementary. Shows a nice chart - Solid vs liquid biopsy https://t.co/UtxlQViUuO #MDxEU17
Michael O'Brien (ANGLE plc): Parsortix: utilise both cfDNA and CTCs from a single patient sample #MDxEU17
7:07am April 11th 2017 via Hootsuite
Winter: "No longer a game of chess, more like an infinite game of Minecraft" as far as tackling cancer. #MDxEU17
7:04am April 11th 2017 via Hootsuite
Winter: IDH1 - found in CNS (GBM), AML. For ICC, seen in about 13%. Will do WES for new mutations, looking for circ metabolites #MDxEU17
7:00am April 11th 2017 via Hootsuite
Winter: #MDxEU17 Interhepatic cholangiocarcinoma (ICC) is a cancer w/unmet need '16 ref https://t.co/IMmyudgS5l 4pt analysis, found CNA Ch12
6:59am April 11th 2017 via Hootsuite
Winter: With n=16, 9/16 response on CT correlated w/ctDNA. 3/16 equivocal, rest did not. #MDxEU17
6:56am April 11th 2017 via Hootsuite
Winter: Adv chemorefractory in lung SIRT (selective internal radiation). High level of ctDNA had short OS. May help in pt select #MDxEU17
6:55am April 11th 2017 via Hootsuite
Winter: KRAS concord 92%; up to 1500 days, one had KRAS wt but ctDNA mutant. (But tissue not sampled again.) #MDxEU17
6:52am April 11th 2017 via Hootsuite
Winter: Showed tumor vs plasma mutation status. Time from FFPE KRAS, and detection in ctDNA in refractory population. <1y to 3y #MDxEU17
6:51am April 11th 2017 via Hootsuite
Winter: #MDxEU17 Rcent review https://t.co/JAE19BAuNH PERFORM clin trial for CT / MRI, Looking at KRAS status with mCRC
6:50am April 11th 2017 via Hootsuite
Winter: Intra-arterial brachytherapy - use bloodflow to hepatic mets, to use perfusion imaging #MDxEU17
6:47am April 11th 2017 via Hootsuite
Winter: First is vessel embolisation, treated with Yttrium-90 spheres, followed by Y90 PET to see where internal radiation is #MDxEU17
Winter: She takes care of many pts at the end of disease. Liver MDT - Figure from '14 ref https://t.co/rEs8gFvNLK 2-part procedure #MDxEU17
6:46am April 11th 2017 via Hootsuite
Helen Winter (Univ Oxford) Monitoring and sequencing cell-free DNA in pts receiving selective internal radiation #MDxEU17
6:45am April 11th 2017 via Hootsuite
Q: Outcome and OS for pts w/T790M? Plagnol: Need more pts to answer this question completely, trend promising #MDxEU17
6:44am April 11th 2017 via Hootsuite
Plagnol: A2 About 3-5% over 50yo have intriguing KRAS or other mutations. #MDxEU17
6:43am April 11th 2017 via Hootsuite
Q: Healthy volunteers? Plagnol: A key question; answer is 'it depends on the cohort'. 50yo vs. young people, smokers etc. #MDxEU17
6:42am April 11th 2017 via Hootsuite
Q: Sure that TP53 is in the tumor in example? Plagnol: Seen in other pts, where TP53 doesn't change. Intriguing. #MDxEU17
Plagnol: Building the case with clinical data to support widespread use. #MDxEU17
6:41am April 11th 2017 via Hootsuite
Plagnol: Accumulating evidence support its use as a replacement for tissue biopsy. Commercial avail in US this year (2017) #MDxEU17
6:40am April 11th 2017 via Hootsuite
Plagnol: Many questions remain - what about TP53 mutants that stay steady thru treatment? #MDxEU17
Plagnol: T790M det in 50% of NSCLC pts, detected down to 0.1% MAF. Freq of T790M showed no correlation to response #MDxEU17
6:38am April 11th 2017 via Hootsuite
Plagnol: 'Rather than rush a product to market", want to design clinical studies. '17 ref https://t.co/gJBJ0r2zPo T790M det #MDxEU17
6:37am April 11th 2017 via Hootsuite
Plagnol: Correlation of mutational profile pre-trtmt and ctDNA allele fx response post-treatment #MDxEU17
6:36am April 11th 2017 via Hootsuite
Plagnol: Showed sensitivity data down to 0.5%. Showed pt data showed complete metabolic response w/T790M resist mut #MDxEU17
6:34am April 11th 2017 via Hootsuite
Plagnol: Their InVision panel covers Fusions, SNVs, indels, amplifications. Some with full gene coverage, ALK/RET fusions. #MDxEU17
6:31am April 11th 2017 via Hootsuite
Vincent Plagnol (Inivata UK) Clinical impact of a high-sensitivity ctDNA assay ana analytics for low freq mutations #MDxEU17
6:30am April 11th 2017 via Hootsuite
Palmer: EGFR down to 0.05% others at 0.5% (T790M, Ex 19 del). Cp to Roche on FFPE, not 100% identical (due to different targets) #MDxEU17
5:42am April 11th 2017 via Hootsuite
Palmer: Their tech for sensitivity is 0.05% to 0.5%. Have FFPE assay kits (with validated sens) and applied to cfDNA #MDxEU17
5:41am April 11th 2017 via Hootsuite
Palmer: pi-codes can be individually assayed then blended for readout. Can multiplex 40 individual PCRs. #MDxEU17
5:39am April 11th 2017 via Hootsuite
Palmer: 50 um discs have about 16K unique barcodes. discs have either probes or immunoassays. SA-PE fluor. Biotinylated amplicons #MDxEU17
5:37am April 11th 2017 via Hootsuite
Palmer: Presence in Taiwan, mfg in China, also south SF CA. a circular 50um silicon ring, with an optical barcode on the chip#MDxEU17
5:36am April 11th 2017 via Hootsuite
Stuart Palmer (PlexBio Taiwan): Multiplex assay on liquid biopsy: practical approach for CDx by nCode Technology #MDxEU17
5:35am April 11th 2017 via Hootsuite
Eccleston: Have plans for testing in the us 2019-2021, sample prospectively collected now. #MDxEU17
5:34am April 11th 2017 via Hootsuite
Eccleston: Their CE mark, reduces unncec. colonoscopies by 20%, detects >90% CRC. Repro studies cp manual to automated #MDxEU17
5:32am April 11th 2017 via Hootsuite
Eccleston: Via stool, ID false-pos FIT test. 95% with positive FIT do not have CRC, all get colonoscopy. #MDxEU17
5:26am April 11th 2017 via Hootsuite
Eccleston: Screening in Copenhagen - 30K prospective, longitudinal. Triage test - Me-Nuc and total Nuc (methylated, and total) #MDxEU17
5:25am April 11th 2017 via Hootsuite
Eccleston: Only 10uL plasma needed, five types of nucleosome types captured and detected. Five clinical trials ongoing #MDxEU17
5:24am April 11th 2017 via Hootsuite
Mark Ecleston (Volition, Belgium): Tu.Q triage colorectal cancer screening test #MDxEU17 Uses simple ELISA technology (capture, 2nd Ab det)
5:23am April 11th 2017 via Hootsuite
Santhanam: Shows Lab Cerba data - clear Z-score differentiation between positive and negatives. Shows multi-analyte data (all 3) #MDxEU17
5:16am April 11th 2017 via Hootsuite
